TARA Biosystems logo — Offering cutting-edge, mature human cardiac tissue models to...

TARA Biosystems

Offering cutting-edge, mature human cardiac tissue models to accelerate the development of safe and effective new medicines.

Founded 2014 Series A Total: $21.25M Biotechnology

General Information

Company Name TARA Biosystems
Founded Year 2014
Industries Biotechnology
Funding Stage Series A
Social

Get notified when TARA Biosystems moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About TARA Biosystems

Tara Biosystems is a biotechnology startup founded in 2014, with a strong focus on revolutionizing the development of new medicines. By utilizing cutting-edge human cardiac tissue models, the company aims to expedite the process of drug discovery and safety evaluation. The Series A investment received on 17 November 2021 from New York Ventures underlines the potential and confidence in Tara Biosystems’ innovative approach. Their commitment to advancing predictive cardiac tissue models demonstrates a dedication to making the pharmaceutical development process faster, safer, and more dependable. This innovative startup holds promise in significantly accelerating the delivery of safe and effective new medicines to market.

Taxonomy: Drug Discovery, Stem Cell Research, Cardiac Tissue Models, Translational Medicine, Predictive Modeling, Pharmaceutical Development, In Vitro Testing, Safety Evaluation, Contractile Force Measurement, Human Tissue Engineering, Medical Innovation

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 1 •••• •••• 17 Nov 2021
Series A •••••• 1 •••• •••• 05 May 2021
Series A •••••• 9
Investor Investor Investor Investor Investor Investor Investor
•••• ••••
23 Jun 2020
Series A •••••• 1 •••• •••• 01 May 2019
Series A •••••• 3
Investor Investor
•••• ••••
16 Oct 2017

View All 6 Funding Rounds

TARA Biosystems Alternatives & Competitors

TARA Biosystems vs
Curi Bio
Curi Bio United States

Human Data for Next Generation Medicines

Grant
59 employees
AI, Biopharma
TARA Biosystems vs

EXPERTS IN 4D TISSUE MODELS

11 employees
Biotechnology, Life Sciences
TARA Biosystems vs

Pioneering Heart and Vascular Health with Advanced Surgical Solutions and Biomaterials for All Ages

Post Ipo Debt
Hardware, Health Care

FAQ About TARA Biosystems

Offering cutting-edge, mature human cardiac tissue models to accelerate the development of safe and effective new medicines.
TARA Biosystems was founded in 2014.
TARA Biosystems operates in the following industries: Biotechnology.
TARA Biosystems has completed 6 funding rounds, raising a total of $21.25M. The latest funding stage is Series A.
Top alternatives and competitors to TARA Biosystems include Curi Bio, REVIVO BioSystems, Artivion, MaxWell Biosystems, Matrigen. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
TARA Biosystems and Curi Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors TARA Biosystems and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy